Stock Traders Daily flags USD 35.18 resistance for Sanara MedTech stock

Published on 10/16/2026 at 04:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 28.14 million, up 8.93 percent year over year. Merger approval shaped Sanara MedTech stock after 6,372,989 of 6,411,427 votes.

Merger and resistance levels

Sanara MedTech shareholders cast 6,372,989 of 6,411,427 votes for the merger on September 30, 2026.
Second-quarter revenue reached USD 28.14 million, 8.93 percent above the prior-year figure.
Sanara MedTech stock was last at USD 35.09 on October 15, 2026 at 4:00 p.m. ET.
Stock Traders Daily identified USD 35.18 as resistance and USD 35.66 as a target on October 14, 2026.

SMTI, US79957L1008, Illustration mit AI erstellt.

Sanara MedTech (ISIN US79957L1008) generated USD 28.14 million in revenue in the second quarter of 2026, up 8.93 percent from USD 25.83 million a year earlier, according to Zacks on August 11, 2026. A separate October 14 report placed the stock near a USD 35.18 resistance level.

Resistance sets the immediate test

Stock Traders Daily reported on October 14, 2026, that Sanara MedTech was testing resistance at USD 35.18. Its report listed USD 35.66 as a longer-term target and USD 34.95 as mid-term support, while describing near-term sentiment as neutral.

The levels matter because the latest reported quarter contained both growth and pressure on profitability. Sanara MedTech posted a net loss of USD 452,864 in the second quarter of 2026, compared with net income of USD 458,957 in the first quarter, while operating cash flow was USD 2.04 million in the second quarter versus negative USD 2.47 million in the first quarter.

What does the 2026 quarter show?

The revenue comparison is constructive, but the earnings figures point to a less even operating picture. Adjusted earnings per share were USD 0.05 in the second quarter of 2026 in the Zacks report, above the USD 0.02 consensus estimate, while reported diluted earnings per share in the standardized financial data were negative USD 0.05 because the measures use different accounting definitions.

Merger chronology and key dates

The relevant chronology has three dated steps. On August 11, 2026, second-quarter revenue reached USD 28.14 million. On September 30, 2026, shareholders approved the MiMedx transaction with 6,372,989 votes for the merger out of 6,411,427 votes cast, as StockWatch reported on October 1, 2026. On October 14, 2026, Stock Traders Daily identified USD 35.18 as resistance.

The merger process also carried an October 15, 2026 Hart-Scott-Rodino waiting-period date in the StockWatch report. For the stock, that corporate event and the USD 35.18 technical level provide the clearest current reference points.

Last Nasdaq quote and valuation

Sanara MedTech was last at USD 35.09 on Nasdaq on October 15, 2026 at 4:00 p.m. ET. Its market capitalization was USD 322.4 million, and its 52-week range was USD 16.05 to USD 35.52 as of that date.